Cystamine and cysteamine prevent 3‐NP‐induced mitochondrial depolarization of Huntington's disease knock‐in striatal cells
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Cystamine significantly improved motor deficits and extended survival in mouse models of Huntington's disease (HD); however, the precise mechanism(s) by which cystamine and the related compound cysteamine are beneficial remain to be elucidated. Using clonal striatal cell lines from wild‐type (ST HdhQ7/HdhQ7) and mutant huntingtin knock‐in (ST HdhQ111/HdhQ111) mice, we have tested the hypothesis that cystamine and cysteamine could be beneficial by preventing the depolarization of mitochondria in cell cultures. Treatment with 3‐nitroproprionic acid (3‐NP), a mitochondrial complex II inhibitor, induces mitochondrial depolarization and cell death of mutant HD striatal cells but not of wild‐type cells. The 3‐NP‐mediated decrease in the mitochondrial membrane potential was attenuated by 50 µ m cystamine and completely inhibited by 250 µ m cystamine. Similar results were obtained using cysteamine (50–500 µ m). In addition, both cystamine and cysteamine significantly attenuated the 3‐NP‐induced cell death. Treatment of mutant HD striatal cells with 3‐NP resulted in a robust decrease in the cellular and mitochondrial levels of glutathione (GSH) compared with cells exposed to the vehicle alone. Pre‐treatment of the cells with cystamine and cysteamine completely prevented the 3‐NP‐mediated decrease in cellular and mitochondrial GSH levels. Incubation with l‐buthionine (S,R) sulfoximine (BSO) 250 µ m in combination with cystamine (250 µ m) or cysteamine (250 µ m) prior to being treated with 3‐NP completely prevented the beneficial effects of cystamine and cysteamine on the 3‐NP‐mediated mitochondrial depolarization. These results demonstrate that cystamine and cysteamine prevent the 3‐NP‐induced mitochondrial depolarization of HD striatal cell cultures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979 · cited 2×
“These protein aggregates constitute a striking neuropathological hallmark of HD; however, their potential contribution to HD pathogenesis remains uncertain (Arrasate et al., 2004; Schaffar et al., 2004).”
BackgroundGriffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683
Gauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Zhao, K., Zhao, G.-M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402999200 · Cited by 782 · cited 2×
“…strategy in HD may include the prevention of mitochondria dysfunction and oxidative stress damage (Hersch, 2003), and in this regard it would be particularly interesting to examine in HD the beneficial effects of mitochondria-targeted antioxidants (Jauslin et al., 2003; Zhao et al., 2004).”
BackgroundMitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758 · cited 4×
“Because mitochondria dysfunction may play an important role in the pathogenesis of HD (Beal, 1994; Gu et al., 1996; Browne et al., 1997; Panov et al., 2002), we have tested the hypothesis that cystamine and cysteamine could be”
BackgroundInfluentialMutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro
Trushina, E., Dyer, R. B., Badger, J. D., Ure, D., Eide, L., Tran, D. D., Vrieze, B. T., Legendre-Guillemin, V., McPherson, P. S., Mandavilli, B. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.8195-8209.2004 · Cited by 520
Choo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515 · cited 2×
“…et al., 2004; Trushina et al., 2004), abnormal transcriptional regulation (Cha, 2000), synaptic dysfunction (Li et al., 2003), excitotoxic and oxidative damage (Beal, 1996; Browne et al., 1997, 1999) and mitochondria dysfunction (Browne et al., 1997; Panov et al., 2002; Choo et al., 2004).”
BackgroundMethodSelf-citationTherapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391 · cited 3×
“Compounds with significant beneficial effects in HD mouse models include minocycline (Chen et al., 2000; Hersch et al., 2003), creatine (Matthews et al., 1998), coenzyme Q10 (Schilling et al., 2001; Ferrante et al., 2002), suberoylanilide hydroxamic acid (Hockly et al., 2003) and riluzole (Rosas et al., 1999).”
Background
Cited by
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases
Trushina, E., & McMurray, C. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.056 · Cited by 439
Role of manganese in neurodegenerative diseases
Bowman, A. B., Kwakye, G. F., Herrero Hernández, E., & Aschner, M. (2011) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2011.08.144 · Cited by 395
Dysregulation of Glutathione Homeostasis in Neurodegenerative Diseases
Johnson, W. M., Wilson-Delfosse, A. L., & Mieyal, J. J. (2012) · Nutrients · doi:10.3390/nu4101399 · Cited by 353
Proteomic and oxidative stress analysis in human brain samples of Huntington disease
Sorolla, M. A., Reverter-Branchat, G., Tamarit, J., Ferrer, I., Ros, J., & Cabiscol, E. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.05.014 · Cited by 301
Metadata
- Authors
- Mao, Z., Choo, Y. S., & Lesort, M.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2006-04
- Volume
- 23
- Issue
- 7
- Pages
- 1701-1710
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W2148589294
- Cited by
- 74
- References
- 13
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cystamine and cysteamine prevent 3‐NP‐induced mitochondrial depolarization of Huntington's disease knock‐in striatal cells. https://app.cochat.ai/papers/10.1111/j.1460-9568.2006.04686.x
- The paper
- Mao, Z., Choo, Y. S., & Lesort, M. (2006). Cystamine and cysteamine prevent 3‐NP‐induced mitochondrial depolarization of Huntington's disease knock‐in striatal cells. European Journal of Neuroscience. https://doi.org/10.1111/j.1460-9568.2006.04686.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.